{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T12:53:36Z","timestamp":1777121616674,"version":"3.51.4"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T00:00:00Z","timestamp":1748476800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T00:00:00Z","timestamp":1748476800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Clin Oncol"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1038\/s41571-025-01034-w","type":"journal-article","created":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T09:09:01Z","timestamp":1748509741000},"page":"539-540","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Daratumumab and missed sequencing opportunities in transplant-ineligible multiple myeloma: lessons for future trials"],"prefix":"10.1038","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6464-783X","authenticated-orcid":false,"given":"Ghulam Rehman","family":"Mohyuddin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron M.","family":"Goodman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,29]]},"reference":[{"key":"1034_CR1","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1200\/JCO.22.00940","volume":"41","author":"MA Dimopoulos","year":"2023","unstructured":"Dimopoulos, M. A. et al. Overall survival with daratumumab, lenalidomide, and dexamethasone in previously treated multiple myeloma (POLLUX): a randomized, open-label, phase III trial. J. Clin. Oncol. 41, 1590\u20131599 (2023).","journal-title":"J. Clin. Oncol."},{"key":"1034_CR2","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/S1470-2045(25)00018-X","volume":"26","author":"MV Mateos","year":"2025","unstructured":"Mateos, M. V. et al. Bortezomib, melphalan, and prednisone with or without daratumumab in transplant-ineligible patients with newly diagnosed multiple myeloma (ALCYONE): final analysis of an open-label, randomised, multicentre, phase 3 trial. Lancet Oncol. 26, 596\u2013608 (2025).","journal-title":"Lancet Oncol."},{"key":"1034_CR3","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1038\/s41375-024-02505-2","volume":"39","author":"T Facon","year":"2025","unstructured":"Facon, T. et al. Daratumumab\/lenalidomide\/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomes. Leukemia 39, 942\u2013950 (2025).","journal-title":"Leukemia"},{"key":"1034_CR4","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1200\/JCO.21.02734","volume":"41","author":"P Sonneveld","year":"2023","unstructured":"Sonneveld, P. et al. Overall survival with daratumumab, bortezomib, and dexamethasone in previously treated multiple myeloma (CASTOR): a randomized, open-label, phase III trial. J. Clin. Oncol. 41, 1600\u20131609 (2023).","journal-title":"J. Clin. Oncol."},{"key":"1034_CR5","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1038\/s41571-022-00665-7","volume":"19","author":"ERS Cliff","year":"2022","unstructured":"Cliff, E. R. S. & Mohyuddin, G. R. Overall survival as a primary end point in multiple myeloma trials. Nat. Rev. Clin. Oncol. 19, 565\u2013566 (2022).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1034_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-020-07503-y","volume":"20","author":"R Fonseca","year":"2020","unstructured":"Fonseca, R. et al. Frontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myeloma. BMC Cancer 20, 1087 (2020).","journal-title":"BMC Cancer"},{"key":"1034_CR7","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1111\/bjh.18568","volume":"200","author":"T Etekal","year":"2023","unstructured":"Etekal, T. et al. Time-to-event surrogate end-points in multiple myeloma randomised trials from 2005 to 2019: a surrogacy analysis. Br. J. Haematol. 200, 587\u2013594 (2023).","journal-title":"Br. J. Haematol."},{"key":"1034_CR8","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1056\/NEJMoa2303379","volume":"389","author":"J San-Miguel","year":"2023","unstructured":"San-Miguel, J. et al. Cilta-cel or standard care in lenalidomide-refractory multiple myeloma. N. Engl. J. Med. 389, 335\u2013347 (2023).","journal-title":"N. Engl. J. Med."},{"key":"1034_CR9","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","volume":"388","author":"P Rodriguez-Otero","year":"2023","unstructured":"Rodriguez-Otero, P. et al. Ide-cel or standard regimens in relapsed and refractory multiple myeloma. N. Engl. J. Med. 388, 1002\u20131014 (2023).","journal-title":"N. Engl. J. Med."},{"key":"1034_CR10","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1056\/NEJMoa2409029","volume":"392","author":"MA Dimopoulos","year":"2024","unstructured":"Dimopoulos, M. A. et al. Daratumumab or active monitoring for high-risk smoldering multiple myeloma. N. Engl. J. Med. 392, 1777\u20131788 (2024).","journal-title":"N. Engl. J. Med."}],"container-title":["Nature Reviews Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41571-025-01034-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41571-025-01034-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41571-025-01034-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T15:54:53Z","timestamp":1757174093000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41571-025-01034-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,29]]},"references-count":10,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["1034"],"URL":"https:\/\/doi.org\/10.1038\/s41571-025-01034-w","relation":{},"ISSN":["1759-4774","1759-4782"],"issn-type":[{"value":"1759-4774","type":"print"},{"value":"1759-4782","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,29]]},"assertion":[{"value":"29 May 2025","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"G.R.M. declares that his institution has received research funding from Janssen for a phase III trial of which he is a site principal investigator, although he did not receive any personal payments or salary support from Janssen for this trial. A.M.G. declares no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}